Nvidia among investors in xAI’s $20bn capital raise - Bloomberg News
Investing.com - Investec has upgraded Lupin (BOM:LPC) from Hold to Buy and raised its price target to INR2,265.00 from INR2,100.00, citing the company’s positioning to capitalize on the GLP-1 opportunity in India.
The upgrade highlights Lupin’s established ecosystem around diabetes, cardiac care, diagnostics, consumer products, and digital services, which Investec believes will enable the company to benefit from the upcoming semaglutide generic launch in India next year.
Investec noted Lupin’s strong execution in complex generics, including inhalation, niche generics, and recently injectables, which are driving momentum in the U.S. market. The firm also pointed out that Lupin remains a beneficiary of U.S. generic market conditions regardless of tariff situations.
The research firm expects Lupin to show strong performance in fiscal year 2026, followed by some moderation in fiscal year 2027, with earnings per share growth resuming in fiscal year 2028.
Investec’s analysis indicates Lupin is a top-three player in anti-diabetes and cardiac therapies in India, with its consumer business (Lupin Life), Digital Life, and diagnostics operations potentially helping the company capture a larger share of the weight loss management ecosystem.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.